Conferences
17–18 May 2018, Barcelona, Spain
3rd Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics
Key Practical Learning Points of the Summit:
- 360 ° view of Antibody Drug Conjugates (ADC) from key industry players to leverage for the business and scientific adoption
- Emerging discoveries, cutting-edge knowledge, tools, methods, technologies to design and to bring to the clinic safe and efficient ADCs
- Advances accelerating ADC therapies success
We are pleased to invite you to the 3rd Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 17-18, 2018 in Barcelona, Spain.
This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development.
The summit will shed light on:
DISCOVERY, DEVELOPMENT & BIOANALYTICAL STRATEGIES TOWARDS NEXT GENERATION ADC:
- Better understandable, more precise and new targets
- Alternative scaffolds and new payloads
- Optimized conjugation chemistry and stability
- Improved therapeutic index
SUCCESSFUL TRANSLATION INTO CLINIC & CLINICAL PROGRESS:
- ADC to treat tumours of the hematopoietic and lymphoid tissues
- ADC to treat solid tumours
- ADC to treat non-oncology diseases
- ADC - immuno-oncology combinations
- Bispecific - ADC combinations
ESTABLISHING ROBUST MANUFACTURING SUPPLY CHAINS
It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Barcelona in May!
